Advanced Pipeline


Click on programs to see 2014 highlights.
Therapy Phase 1 Phase 2 Phase 3 Marketed
AMPYRA®(dalfampridine)

AMPYRA®(dalfampridine)

  • $366.2 million in 2014 net sales, a 21% increase over 2013
  • More than 100,000 people with MS have tried AMPYRA since launch
Walking in MS
 
 
 
 
ZANAFLEX® (tizanidine HCI)

ZANAFLEX® (tizanidine HCI)

Spasticity
 
 
 
 
QUTENZA® (capsaicin)

QUTENZA® (capsaicin)

Post-Shingles
Nerve Pain
 
 
 
 
DALFAMPRIDINE

DALFAMPRIDINE

  • Initiated Phase 3 clinical trial for chronic post-stroke walking deficits (PSWD) in December 2014
Chronic Post-Stroke
Walking Deficits
 
 
 
 
CVT-301

CVT-301

  • Initiated Phase 3 clinical trial for OFF episodes in Parkinson’s disease in December 2014
Parkinson's Disease
 
 
 
 
PLUMIAZ

PLUMIAZ

Seizure Clusters
 
 
 
 
CIMAGLERMIN ALFA

CIMAGLERMIN ALFA

  • Initiated second Phase 1 heart failure clinical trial in November 2013; results expected in 2015
Heart Failure
 
 
 
 
rHlgM22

rHlgM22

  • Completed first Phase 1 MS clinical trial in 2014
  • Expect to initiate second Phase 1 clinical trial in 2Q 2015
MS
 
 
 
 
CVT-427

CVT-427

Preparing for first Phase 1 clinical trial

Migraine
Migraine